Verastem Oncology

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

6 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Markets & Equities 15 Oct 2026, 02:19 PM IST

Verastem Says Early RAS Drug Data Set a New Bar in Pancreatic Cancer

Verastem Oncology says early clinical data for its KRAS G12D-targeting drug showed responses in pancreatic cancer, a notoriously difficult disease with few effective options. The update comes as the company raises capital and advances the program toward a pivotal phase III study, sharpening investor focus on whether the drug can emerge as a meaningful competitor in one of oncology’s most competitive races.

By RDU Global Wire5 min read

Global Health & Biotech15 Oct 2026, 08:30 AM IST

Verastem Says Early RAS Data Sets New Benchmark as It Raises $250 Million

Verastem Oncology said early clinical data for its RAS-targeted cancer drug has established a new benchmark in a difficult-to-treat tumor type, a claim that could sharpen investor focus on the company’s pancreatic cancer strategy. The announcement came alongside a $250 million equity financing, giving the biotech fresh capital to advance its pipeline while it seeks to convert preliminary signals into a credible late-stage franchise.

5 min readRead →

Global Markets & Equities15 Oct 2026, 06:47 AM IST

Verastem Says Early RAS Drug Data Sets New Bar as It Raises $250 Million

Verastem Oncology is pitching its early pancreatic cancer data as a potential benchmark-setting readout in one of oncology’s most difficult markets, with chief executive Dan Paterson saying the company’s RAS-targeted program has delivered encouraging signs. The disclosure comes alongside a $250 million equity raise, underscoring both the scientific promise and the capital intensity of advancing a late-stage cancer pipeline.

5 min readRead →

Global Health & Biotech15 Oct 2026, 09:30 PM IST

Merck CEO Says Personalized Cancer Vaccine Could Be Made Faster as Pipeline Advances

Merck Chief Executive Robert Davis told CNBC he expects the company’s experimental personalized cancer vaccine to become faster to manufacture over time, signaling a potential shift from early-stage scientific promise toward more scalable production. The comments add fresh attention to a closely watched oncology program that investors view as a possible long-term growth driver for Merck and a broader test case for the commercial viability of personalized cancer immunotherapy.

5 min readRead →

Clean Energy & Climate Transition11 Oct 2026, 11:57 PM IST

Age and Sex May Rewire Cancer Immunity, New Mouse and Human Data Suggest

New experimental and clinical evidence suggests that age and sex can materially alter how the immune system responds to cancer, potentially helping explain why some patients respond differently to immunotherapies. The findings add another layer of complexity to precision oncology, where treatment decisions may increasingly need to account not only for tumor genetics but also for patient biology.

5 min readRead →

Healthcare, Pharma & Life Sciences11 Oct 2026, 04:04 PM IST

Kidwai’s Home Palliative Care Reaches 3,000 as Karnataka Expands Support for Terminally Ill Families

Kidwai Memorial Institute of Oncology has said its home-based palliative care programme in Karnataka has reached more than 3,000 patients and caregivers, underscoring the growing role of community-level support for people living with life-limiting illnesses. Marking World Hospice and Palliative Care Day, the institute highlighted home visits, symptom relief and bereavement support as part of a model that extends care beyond hospital walls.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Verastem Oncology:

Washington, D.C.(3)Dan Paterson(3)